Lufax Holding Ltd Announces Plan to Implement ADS Ratio Change
SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Lufax Holding Ltd ("Lufax" or the "Company") (NYSE: LU and HKEX: 6623), a leading financial services enabler for small business owners in China, today announced that it plans to change the ratio of its...
SWI Capital Holding Ltd. Announces Changes to its Board of Directors and Audit Committee
SINGAPORE and AMSTERDAM, Sept. 30, 2026 /PRNewswire/ -- SWI Capital Holding Ltd. ("SWI" or the "Company") announces changes to the composition of its Board of Directors (the "Board") and Audit Committee. The Board has appointed Ido Shavit as an...
One Understanding, Many Outputs: Iyuno Announces the CLOE Skills Powering Modern Localization
Persistent Contextual Memory lets purpose-built Skills share the same understanding of content across multiple deliverables. BURBANK, Calif., Sept. 30, 2026 /PRNewswire/ -- Iyuno today detailed the first set of 10 CLOE Skills, built around the needs...
ReTo Eco-Solutions, Inc. Announces Share Consolidation
BEIJING, Sept. 29, 2026 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company") today announced that its board of directors approved a combination of its Class A shares, no par value (the "Class A Shares"), on a...
At RelFest Chicago, Relativity Announces KPMG and Three Global Law Firms to Join Relativity claiR Advanced Access Program
News Summary At its annual user conference, RelFest Chicago, Relativity announced that KPMG, Latham & Watkins LLP, Ashurst Perkins Coie and Troutman Pepper Locke have joined the Advanced Access program for its conversational AI experience...
Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
CALGARY, AB, Sept. 29, 2026 /PRNewswire/ -- Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine programs,...
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in...
111, Inc. Announces Establishment of the Special Committee
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three...
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating...
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major...